Healthy
Conditions
Keywords
Eye-tracking, vasopressin
Brief summary
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Detailed description
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. Initial studies have employed intranasal AVP during a socio-emotional eye tracking paradigm and reported effects on both, top-down as well as bottom-up control. Within this context the present study aims to validate the effects of orally administered AVP on top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a saccade/anti-saccade task 45 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine the social and emotion-specific effects of oral vasopressin.
Interventions
DRUGVasopressin
Administration of Vasopressin (20 IU) (oral spray)
DRUGPlacebo
Administration of Placebo (oral spray)
Sponsors
University of Electronic Science and Technology of China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Intervention model description
Randomized placebo-controlled double-blind between-subject design
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent. Normal or corrected-normal version
Exclusion criteria
* History of neuropsychiatric diseases. * History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness. * History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction. * History of renal diseases, including renal stones or renal failure. * History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus * Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food. * Infections such as COVID-19 or influenza, or unexplained fever. * Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg). * History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes. * Blood donation (≤ 1 month prior to administration). * Take oral contraceptives or receive hormonal medications in the three months prior to the experiment. * Pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration | 45 minutes - 75 minutes after treatment | Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions. |
| Error rate of saccade/antisaccade for social versus non-social stimuli after oral vasopressin administration | 45 minutes - 75 minutes after treatment | Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Saccade/antisaccade latency for different facial emotions after oral vasopressin administration | 45 minutes - 75 minutes after treatment | Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions. |
| Error rate of saccade/antisaccade for different facial emotions after oral vasopressin administration | 45 minutes - 75 minutes after treatment | Comparison between emotion-specific saccade/antisaccade error rates between the vasopressin and placebo treatment conditions. |
Countries
China
Contacts
Primary ContactWeihua Zhao, Dr
Outcome results
None listed